US biotech company has initiated GMP development plan for CS-TATI-1 with the initial production of CS-TATI-1 to be performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to treat HIV associated Kaposi Sarcoma. CS-TATI-1 is in preclinical development intended to target HIV TAT, which is an important target to develop new HIV drugs and also address the presentation of KSHV transactivation by HIV TAT. Cannabis Science president and CEO Robert Melamede said, ”Our analysis of utilizing an endosome based transdermal delivery of CS-TATI-1 in our initial studies will be optimal for addressing regulatory compliance concerns and meet the need of patients who are in need of effective localized delivery of the clinical activity of Cannabis Science’s flagship therapeutic agent.” Kaposi Sarcoma is a type of cancerous tumor of connective tissue and is likely to produce nodules or patches that can affect the skin, eye, lungs, liver, stomach, intestine and lymph nodes.
via : Pharmaceutical Business Review
You must be logged in to post a comment.